This paper is in the following e-collection/theme issue:

Cardiovascular Disease Prevention (212) Diabetes (275) Digital Health, Telehealth and e-Innovation in Clinical Settings (574) Gastroenterology and Hepatology (140) Prescribable Digital Interventions (Digital Therapeutics) (47) Innovations and Technology for Healthy Eating Education (503) Innovations and Technology for Physical Activity Education (953) Web-based and Mobile Health Interventions (4132)

Published on in Vol 9 (2025)

This is a member publication of Bibsam Consortium

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/72074, first published .
Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals With Nonalcoholic Fatty Liver Disease: Prospective Single-Arm Feasibility Study

Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals With Nonalcoholic Fatty Liver Disease: Prospective Single-Arm Feasibility Study

Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals With Nonalcoholic Fatty Liver Disease: Prospective Single-Arm Feasibility Study

Authors of this article:

Sigridur Björnsdottir1, 2 Author Orcid Image ;   Hildigunnur Ulfsdottir3 Author Orcid Image ;   Elias Freyr Gudmundsson3 Author Orcid Image ;   Bartosz Dobies3, 4 Author Orcid Image ;   Kolbrun Sveinsdottir3 Author Orcid Image ;   Ari Pall Isberg3 Author Orcid Image ;   Gudlaug E A Magnusdottir3 Author Orcid Image ;   Thrudur Gunnarsdottir3 Author Orcid Image ;   Tekla Karlsdottir3 Author Orcid Image ;   Gudlaug Bjornsdottir5, 6 Author Orcid Image ;   Sigurdur Sigurdsson5, 6 Author Orcid Image ;   Saemundur Oddsson3 Author Orcid Image ;   Vilmundur Gudnason5, 6 Author Orcid Image
Article Authors Cited by (1) Tweetations Metrics

Journals

  1. Sun C, Chen G, Shi C, Cao H, Yang R, Zeng J, Duan X, Sun X, Fan J. Therapeutic Effects of a WeChat Mini-Program on Metabolic Dysfunction–Associated Fatty Liver Disease: Randomized Controlled Trial. Journal of Medical Internet Research 2026;28:e76204 View